NMD Pharma
Rare Disease Therapeutics · Drug Discovery
$37.8Mlatest round · Venture round · Feb 2022 · 4 yr ago
2backers · Inkef, Jeito Capital
50+team · employees, estimated range
11stories in the press
Overview
0 Enable better lives through novel therapies to restore skeletal muscle health About NMD Pharma NMD Pharma is a clinical-stage biotech company dedicated to enabling better lives through novel therapies designed to restore skeletal muscle health.
Funding and backers
Total raised
$37.8M
1 round on record
Latest round
$37.8M
Venture round · Feb 2022 · 4 yr ago
Team
51-200
employees, estimated range
Backers
2
Inkef, Jeito Capital
The money's age
Long since its last round
56 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 15, 2022
Raised a round Venture round $37.8M · YahooFinance
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2022 | $37.8M | — | YahooFinance |
Registers and programsofficial lists and records that name the company
| Legal entity | NMD PHARMA A/S | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious…
Explore the Kyntra Bio site to learn about our oncology and rare disease therapies, pipeline highlights, clinical trials, culture, and…
US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences' Dual Signal Modulator for the Treatment of…
Financials
Total raised
$37.8M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2022 | $37.8M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Jeito CapitalVia a fund
InkefVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness
Read more
Report
NMD Pharma to progress CMT pill despite primary endpoint miss
The biotech is now banking on secondary data signals as it progresses ignaseclant to late-stage trials in Charcot-Marie-Tooth disease.
Read more
Report
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth
Read more
Report
NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference
Aarhus, Denmark, 6 January 2026 - NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that Thomas Holm Pedersen, Chief Executive Officer of
Read more
Report
NMD Pharma To Present Compelling Preclinical Data Highlighting The Potential Of Clc-1 Ion Channel Inhibition To Improve Disease Symptoms And Progression In Musk Myasthenia ...
Read more
Report
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology
Read more
Report
NMD Pharma Receives IND Clearance From The FDA To Initiate A Phase 2 Clinical Trial Of NMD670 In Charcot-Marie-Tooth Disease In The US
Read more
Report
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma Raises €35 Million in a new Financing - New investor Jeito Capital joins current NMD Pharma investors - Proceeds will be used to progress lead clinical programs, expand the number of target indications, and add new R&D capabilities in severe ne
Read more
Report
Report
The winners of the INCUBA Award 2022
The biotech company NMD Pharma and business angel Bo Wase received the INCUBA Awards Thursday October 6th in the categories
Read more
Report
Show more news